Iterum Therapeutics’ (ITRM) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a report published on Monday morning,Benzinga reports.

Other equities analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iterum Therapeutics in a research report on Monday, December 22nd. Maxim Group downgraded shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $9.00.

Iterum Therapeutics Stock Performance

Shares of ITRM opened at $0.07 on Monday. Iterum Therapeutics has a one year low of $0.03 and a one year high of $1.42. The stock has a 50-day moving average price of $0.24 and a 200 day moving average price of $0.43. The company has a market capitalization of $3.75 million, a P/E ratio of -0.09 and a beta of 2.96.

Hedge Funds Weigh In On Iterum Therapeutics

Hedge funds have recently bought and sold shares of the company. OneDigital Investment Advisors LLC raised its stake in Iterum Therapeutics by 18.6% during the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after buying an additional 30,000 shares in the last quarter. Virtu Financial LLC bought a new position in Iterum Therapeutics during the 3rd quarter worth approximately $32,000. Jane Street Group LLC acquired a new position in shares of Iterum Therapeutics in the 2nd quarter worth approximately $92,000. Alchemi Wealth LLC acquired a new position in shares of Iterum Therapeutics in the 4th quarter worth approximately $90,000. Finally, Apollon Financial LLC increased its holdings in shares of Iterum Therapeutics by 151.8% in the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock valued at $211,000 after acquiring an additional 380,000 shares during the last quarter. 9.21% of the stock is currently owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).